of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. We would cease to be an emerging growth company on the date that is the earliest of: (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) December 31, 2021; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

        The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

ChIP assays were carried out using the EZ ChipTM Assay kit (Millipore) according to the manufacturer’s instructions. Briefly, cells were crosslinked with 1% formaldehyde at room temperature for 15 min, washed twice in PBS and lysed in SDS lysis buffer. Chromatin fragments were prepared by sonicating lysates on ice. Then, lysates were incubated with antibodies against HIF-1α, HIF-2α (Novus Biologicals), RNA polymerase II, or IgG (Millipore). Immunoprecipitated complexes were collected using protein G-agarose beads. The pellets were washed with Elution buffer and incubated at 65 °C for 4 h to reverse the cross-link by formaldehyde. They were then digested with 50 μg/ml proteinase K for 1 h. Dissociative DNA were purified using the Cycle Pure Kit (Omega) and subjected to PCR amplification. The primers used for amplification of the HRE and negative control segments of the promoter were as follows: HRE, 5 -AGG AAA TGA ATC AAT GTA AC -3 (forward) and 5- TAA GCA ACT CCA CCA AAA -3 (reverse); negative control, 5- TCC GCT CTT CTT CCC TCA -3 (forward) and 5– TGC GAA GCT GCT CAG TCG -3 (reverse).

Josh mentioned in his latest post that NSAID’s reduce cancer risk and that Celebrex may be the safest. Carlos has referred on several occasions to his studies on digoxin as cancer preventative. A new study today in Nature Biomedical Engineering (Backman) used partial wave spectroscopic microscopy to look at chromatin in cancer cells. This revealed that a more heterogeneous and disordered chromatin packing density was related to greater cancer cell survival whereas a more ordered packing density lead to greater cell death with chemo. They then combined digoxin with Celebrex, which they referred to as chromatin protection therapeutics, and these drugs restructured the chromatin so that every single cancer cell died because they could not respond to the chemo. This worked in all cancers that they tried it on. Very promising.

Boger, R. H. & Ron, E. S. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Alternative medicine review : a journal of clinical therapeutic 10, 14–23 (2005).

Stanger, O. & Weger, M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med. 41, 1444–1454 (2003).

So he looked at my huge list of supplements and rapamycin ( which he had never heard of). So ID says to me: 1. You know all of these “vitamins” that you take have been “proven” to do more harm than good. 2. Look at you, you’d better stay out of the sun, you’ll get skin cancer ( ignoring my vit D level of 60, and that 90% of skin cancers are benign c/w most cancers associated with low D that will actually KILL YOU). 3. What’s this rapamucin stuff you’re on? You know you shouldn’t take antibiotics for too long. 4. Why do you want an echo? Did you have a heart attack? 5.Where’s your PSA level? After all, it’s all we’ve got. ( So better to get a test that doesn’t effect mortality rates because “it’s all we’ve got”.

Cleveland BioLabs, Inc. (NasdaqCM:CBLI ) is a biotechnology company leveraging its proprietary discoveries around programmed cell death to develop a robust pipeline of drugs for multiple medical and defense applications. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. CBLI’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias (pathologies developed as a result of blocking blood flow to a part of the body). Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.

激素治疗癌症最主要的优势是不会引起类似细胞毒物质一样的骨髓抑制。精确的抗癌机制不是完全清楚。最常用于治疗乳腺癌和前列腺癌，以及子宫内膜癌和子宫癌。此类药物包括：

Li, C. et al. Qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-kappaB signaling pathway. PLoS ONE 9, e104255, 10.1371/journal.pone.0104255 (2014).

A weighted meta-regression using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential moderator variables on the WMD in ADMA concentrations between statin and placebo group19,21.

Our market is subject to intense competition. If we are unable to compete effectively, Aramchol or any other potential product candidate that we develop may be rendered suboptimal, noncompetitive or obsolete.